Internal Server Error

Discern - About the company

Discern is an unfunded company based in Rockville (United States). It operates as a Developer of skin biopsy tests for identifying Alzheimer disease pathology. Discern has not raised any funding yet. The company has 44 active competitors, including 18 funded and 2 that have exited. Its top competitors include companies like C₂N Diagnostics, ALZpath and NeuroDex.

Company Details

Developer of skin biopsy tests for identifying Alzheimer disease pathology. This diagnostic tool analyzes skin samples to determine the presence or absence of biological markers associated with the condition. The process involves collecting a tissue sample from a patient, which is then incubated and evaluated in a laboratory setting. Results are provided to healthcare providers to assist in clinical assessments and the management of patients experiencing cognitive decline. The procedure is intended to support diagnostic accuracy for individuals presenting with symptoms of dementia.
Key Metrics
Location
Rockville, United States
Stage
Unfunded
Ranked
59th among 59 competitors
Similar Companies
Sign up to download Discern's company profile

Discern's funding and investors

Discern has not raised any funding rounds yet.

chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Discern's Competitors and alternates

Top competitors of Discern include C₂N Diagnostics, ALZpath and NeuroDex. Here is the list of Top 10 competitors of Discern, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for C₂N Diagnostics
C₂N Diagnostics
2007, St. Louis (United States), Series B
Developer of diagnostics and therapies for Alzheimer's disease
$35M
58/100
2nd
Logo for ALZpath
ALZpath
2020, Carlsbad (United States), Series A
Developer of diagnostic solutions for Alzheimer's Disease
$8.41M
55/100
3rd
Logo for NeuroDex
NeuroDex
2018, Natick (United States), Seed
Manufacturer of diagnostic tools for Alzheimer's disease
$1.36M
54/100
4th
Logo for Amydis Diagnostics
Amydis Diagnostics
2013, San Diego (United States), Series A
Developer of diagnostics test for detection of Alzheimer's disease
$8.69M
53/100
5th
Logo for Todos Medical
Todos Medical
2009, Rehovot (Israel), Public
Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders
-
47/100
6th
Logo for DiamiR
DiamiR
2009, Monmouth Junction (United States), Funding Raised
Developer of minimally invasive diagnostic tests
-
 
45/100
7th
Logo for ADmit Therapeutics
ADmit Therapeutics
2017, Barcelona (Spain), Series A
Provider of diagnostic services for early detection of Alzheimer's disease
$12.9M
42/100
8th
Logo for Lucent Diagnostics
Lucent Diagnostics
2023, Billerica (United States), Unfunded
Developer of a biomarker blood test for the diagnosis of Alzheimer's disease
-
-
39/100
9th
Logo for bioLOCKEY Healthworks
bioLOCKEY Healthworks
2023, Bengaluru (India), Seed
Developer of point-of-care diagnostics and novel biologics by Nanobody discovery platform
$478K
37/100
10th
Logo for Veravas
Veravas
2017, Oakdale (United States), Series A
Provider of platform to manage sample preparation and diagnostic solutions
$25M
37/100
59th
Logo for Discern
Discern
Rockville (United States), Unfunded
Developer of skin biopsy tests for identifying Alzheimer disease pathology
-
-
-
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Discern's competitors? Click here to see the top ones

Discern's Investments and acquisitions

Discern has made no investments or acquisitions yet.

Reports related to Discern

Here is the latest report on Discern's sector:

FAQs about Discern

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford